Abstract | AIM: METHODS: Platelet aggregation was assessed by the highly sensitive particle counting method using laser-light scattering. RESULTS: Large platelet aggregation induced by adenosine diphosphate ( ADP, 3 microM) was 2.6+/-0.4 (x10(7)) (SE) in hypertensive patients treated with losartan (72+/-3 years old, n=10) while it was 3.9+/-0.6 in hypertensive patients treated with candesartan (70+/-5 years old, n=6; p=0.056). Large platelet aggregation induced by thromboxane A2 receptor agonist, U46619 (10 microM), was 2.8+/-0.5 (x10(7)) in hypertensive patients treated with losartan while it was 5.1+/-0.9 in hypertensive patients treated with candesartan (p=0.033). Clinical characteristics including the control of blood pressure did not differ between the two groups ( losartan 136+/-5/73+/-3 mmHg vs. candesartan 135+/-4/76+/-5). CONCLUSION: Thus, losartan may have the possibility to inhibit platelet activation in patients with hypertension independent of blood pressure reduction. Antiaggregatory properties may be independent of angiotensin II type 1 receptor or of antihypertensive actions. The favorable effects of losartan on reduction of adverse cardiovascular events among hypertensive patients may be at least partly mediated by inhibition of platelet activation.
|
Authors | Yuki Sato, Satoshi Fujii, Shogo Imagawa, Kazue Ohmura, Yoshinori Ohmura, Yasuhiro Andoh, Jie Dong, Naoki Ishimori, Tomoo Furumoto, Hiroyuki Tsutsui |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 14
Issue 1
Pg. 31-5
(Feb 2007)
ISSN: 1340-3478 [Print] Japan |
PMID | 17332690
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Biphenyl Compounds
- Platelet Aggregation Inhibitors
- Tetrazoles
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
- Losartan
- candesartan
|
Topics |
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
(therapeutic use)
- Aged
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Biphenyl Compounds
- Cardiovascular Diseases
(prevention & control)
- Female
- Humans
- Hypertension
(blood, drug therapy)
- Light
- Losartan
(therapeutic use)
- Male
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
- Platelet Function Tests
- Scattering, Radiation
- Tetrazoles
(therapeutic use)
- Therapeutic Equivalency
|